Chemotherapy for low-grade gliomas: When? How? How long?

Neuro-Oncology

Volumn 12, Issue 10, 2010, Pages 1013-

  Weller, Michael ^a  

^a EANO ^*  (Romania)

Author keywords

[No Author keywords available]

Indexed keywords

PROCARBAZINE; TEMOZOLOMIDE; VINCRISTINE;

ASTROCYTOMA; CANCER CHEMOTHERAPY; CANCER GRADING; CANCER RADIOTHERAPY; CELL DEATH; CELL PROLIFERATION; DRUG SAFETY; DRUG TOLERABILITY; EDITORIAL; GLIOMA; HUMAN;

ANTINEOPLASTIC AGENTS; BRAIN NEOPLASMS; GLIOMA; HUMANS;

EID: 78650146155     PISSN: 15228517     EISSN: 15235866     Source Type: Journal    
DOI: 10.1093/neuonc/noq137     Document Type: Editorial

References (4)

1. Peyre M, Cartalat-Carel S, Meyronet S, et al. Prolonged response without prolonged chemotherapy: a lesson from PCV chemotherapy in low-grade gliomas. Neuro-Oncology. 2010;12:1078-1082.
2. Kaloshi G, Benouaich-Amiel A, Diakite F, et al. Temozolomide for lowgrade gliomas: predictive impact of 1p/19q loss on response and outcome. Neurology. 2007;68:1831-1836.
3. Wen PY, Macdonald DR, Reardon DA, et al. Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol. 2010;28:1963-1971.
4. Ricard D, Kaloshi G, Amiel-Benouaich A, et al. Dynamic history of lowgrade gliomas before and after temozolomide treatment. Ann Neurol. 2007;61:484-490.